BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-25 out of 59 found
  Current Search:  vivitrol: 59     

HTML
100%
Alkermes Retains Neutral Rec
We maintain our Neutral rating on Alkermes, Inc.

(ALKS) with a price target of $11.50.

Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system...

Individual.com:  Feb 9 2010 1:26PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Retains Neutral Rec
We maintain our Neutral rating on Alkermes, Inc.

(ALKS - Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and...

Zacks.com:  Feb 9 2010 3:12AM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Retains Neutral Rec - Analyst Blog
We maintain our Neutral rating on Alkermes, Inc.

( ALKS ) with a price target of $11.50.

Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous...

Benzinga.com:  Feb 8 2010 10:09PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
Record Sales of RISPERDAL CONSTA Company Expands Proprietary Pipeline to Include Long-Acting Versions of Two Blockbuster Medications WALTHAM, Mass.--(BUSINESS WIRE)--Feb 4, 2010 - Alkermes, Inc.

(NASDAQ: ALKS) today reported financial results for its third...

Pharma Live:  Feb 7 2010 2:24AM
Matching: vivitrol
Find similar documents
HTML
100%
Strong 3Q Sales for Alkermes
Alkermes' ALKS reported fiscal third-quarter results with sales coming in slightly above our expectations.

We will maintain our fair value estimate, though, as this performance does not change our long-term outlook for the firm.

Revenues rose to $44 million...

Morningstar.ca:  Feb 6 2010 3:40AM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
WALTHAM, Mass.-- (BUSINESS WIRE) -- Alkermes, Inc.

(NASDAQ: ALKS) today reported financial results for its third quarter of fiscal 2010, which ended on December 31, 2009.

Financial highlights: Quarterly revenues of $44.2 million, driven by record...

SmartBrief:  Feb 5 2010 2:37AM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes, Inc. (ALKS) Third-Quarter Review
Analysts at Leerink Swann have released a report reviewing the third-quarter at Alkermes, Inc.

(NASDAQ: ALKS ).

The company reported results for the third-quarter yesterday.

Alkermes, Inc.

reported revenue of $44 million, which was above analysts...

Benzinga.com:  Feb 5 2010 8:20PM
Matching: vivitrol
Find similar documents
HTML
100%
Lower Q3 Loss for Alkermes - Analyst Blog
Alkermes Inc.

( ALKS ) reported a third quarter fiscal 2010 net loss of 3 cents per share (excluding items but including stock based compensation) compared with a loss of 9 cents in the year-ago period (excluding the impact of the termination of the...

Benzinga.com:  Feb 5 2010 6:57PM
Matching: vivitrol
Find similar documents
HTML
100%
Analyst upgrades Alkermes on sales of Risperdal Consta, and expected diabetes drug ruling
NEW YORK Strong sales of a schizophrenia drug during the third quarter prompted an analysts to upgrade shares of Alkermes Inc.

on Friday.

Shares jumped 10 percent, or $1.10, to $11.62 in premarket trading.

Jefferies and Co.

analyst David Windley...

DCExaminer.com:  Feb 5 2010 2:37PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
4:00 PM EST News source: Business Wire Alkermes, Inc.

(NASDAQ: ALKS) today reported financial results for its third quarter of fiscal 2010, which ended on December 31, 2009.

Financial highlights: Other recent highlights: The record RISPERDAL CONSTA sales in...

Genetic Engineering News:  Feb 5 2010 7:39AM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes reports 3Q loss, smaller than expected
CAMBRIDGE, Mass.

-- Biotech drug developer Alkermes Inc.

on Thursday reported a fiscal 2010 third-quarter loss on lower revenue, but the results topped Wall Street expectations.

Alkermes said it lost $6.8 million, or 7 cents per share, in the quarter...

Forbes.com:  Feb 5 2010 1:15AM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes reports fiscal 3rd-quarter loss on revenue dip, but smaller than expected
CAMBRIDGE, MASS.

Biotech drug developer Alkermes Inc.

on Thursday reported a fiscal 2010 third-quarter loss on lower revenue, but the results topped Wall Street expectations.

Alkermes said it lost $6.8 million, or 7 cents per share, in the quarter ended...

DCExaminer.com:  Feb 5 2010 12:02AM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
- Record Sales of RISPERDAL CONSTA- - Company Expands Proprietary Pipeline to Include Long-Acting Versions of Two Blockbuster Medications - WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc.

(NASDAQ: ALKS) today reported financial results for its third quarter...

Poten & Partners:  Feb 5 2010 11:44AM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Inc. Reports Operating Results (10-Q)
Posted by: gurufocus (IP Logged) Alkermes Inc.

(ALKS) filed Quarterly Report for the period ended 2009-12-31.

Alkermes Inc.

has a market cap of $1.05 billion; its shares were traded at around $11.09 with a P/E ratio of 13.1 and P/S ratio of 3.3.

ALKS is...

Guru Focus:  Feb 4 2010 10:30PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
Cost of goods manufactured and sold for the quarter ended December 31, 2009, was $10.1 million, of which $8.4 million related to RISPERDAL CONSTA, $1.1 million related to VIVITROL and $0.6 million related to the manufacture of polymer for exenatide once...
FinanzNachrichten.de:  Feb 4 2010 9:06PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Alkermes, Inc.

(NASDAQ: ALKS) today reported financial results for its third quarter of fiscal 2010, which ended on December 31, 2009.

Financial highlights: Quarterly revenues of $44.2 million, driven by record manufacturing...

Yahoo! Canada:  Feb 4 2010 11:01PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
WALTHAM, Mass.Alkermes, Inc.

(NASDAQ: ALKS - News) today reported financial results for its third quarter of fiscal 2010, which ended on December 31, 2009.

Financial highlights: Quarterly revenues of $44.2 million, driven by record manufacturing and royalty...

Business Wire via Yahoo!:  Feb 4 2010 10:07PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
Record Sales of RISPERDAL CONSTA Company Expands Proprietary Pipeline to Include Long-Acting Versions of Two Blockbuster Medications WALTHAM, Mass.--(BUSINESS WIRE)--Alkermes, Inc.

(NASDAQ: ALKS) today reported financial results for its third quarter of...

Business Wire:  Feb 4 2010 9:34PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
Alkermes, Inc.

(NASDAQ: ALKS) today reported financial results for its Financial highlights: Quarterly revenues of $44.2 million, driven by record manufacturing and royalty revenues from RISPERDAL CONSTA.

Worldwide sales of RISPERDAL CONSTA by Janssen,...

EuroInvestor.co.uk:  Feb 4 2010 9:11PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes reports 3Q loss, smaller than expected
CAMBRIDGE, Mass.

(AP) -- Biotech drug developer Alkermes Inc.

on Thursday reported a fiscal 2010 third-quarter loss on lower revenue, but the results topped Wall Street expectations.Alkermes said it lost $6.8 million, or 7 cents per share, in the quarter...

Yahoo! Canada:  Feb 4 2010 11:33PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
-- Record Sales of RISPERDAL(R) CONSTA(R)-- -- Company Expands Proprietary Pipeline to Include Long-Acting Versions of Two Blockbuster Medications -- WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc.

(NASDAQ: ALKS) today reported financial results for its...

Street Insider:  Feb 4 2010 9:36PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Reports Third Quarter Fiscal 2010 Financial Results
WALTHAM, Mass.

- (BUSINESS WIRE) - Alkermes, Inc.

(NASDAQ: ALKS) today reported financial results for its third quarter of fiscal 2010, which ended on December 31, 2009.

Financial highlights: Other recent highlights: "The record RISPERDAL CONSTA sales in...

NewsBlaze:  Feb 4 2010 9:09PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Corporate Presentation to be Webcast at the BIO CEO & Investor Conference
Alkermes, Inc.

(ALKS) announced today that its corporate presentation will be webcast live by the Biotechnology Industry Organization on Monday, February 8, 2010, at 3:00 p.m.

ET from The Waldorf Astoria Hotel in New York City.

The presentation may be...

Boston Globe:  Feb 1 2010 10:16PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Corporate Presentation to be Webcast at the BIO CEO & Investor Conference
Companies mentioned in this article: Alkermes, Inc.

WALTHAM, Mass.

-- (BUSINESS WIRE) -- Alkermes, Inc.

(NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by the Biotechnology Industry Organization on Monday, February 8,...

Freshnews.com:  Feb 1 2010 9:40PM
Matching: vivitrol
Find similar documents
HTML
100%
Alkermes Corporate Presentation to be Webcast at the BIO CEO & Investor Conference
Companies mentioned in this article: Alkermes, Inc.

WALTHAM, Mass.

-- (BUSINESS WIRE) -- Alkermes, Inc.

(NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by the Biotechnology Industry Organization on Monday, February 8,...

Freshnews.com:  Feb 1 2010 9:40PM
Matching: vivitrol
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.